About the company

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.